Is there a difference in the durability of CR based on the dosage of pembrolizumab used in metastatic melanoma?
In this study, doses of 2mg/kg Q3wks, 10mg/kg Q3wks and 10mg/kg Q2wks were used. What did the majority of these patients in CR receive?
1 Answer
Mednet Member
Medical Oncology · Sediman Cancer Center/University Hospitals of Cleveland Case Medical Center
Answered on
This a great question and highlights the drug dosing and development process of the use of Pembrolizumab in metastatic Melanoma. In Keynote-002, Pembrolizumab was studied in the does of 2mg/kg and 10mg/kg vs chemotherapy and the CR responses were 2 vs 3% in the Pembrolizumab arms. In Keynote-006, Pe...
Join for free or sign in to see the full answer